Valion Bio, Inc. Investment Income, Interest
Valion Bio, Inc. (VBIO) reported Investment Income, Interest of $11.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-14
- Valion Bio, Inc. investment income, interest for the quarter ending 2026-06-30 was $11.00K, a 266.67% increase year-over-year.
- Valion Bio, Inc. investment income, interest for the quarter ending 2026-03-31 was $24.00K, a 500.00% increase year-over-year.
- Valion Bio, Inc. investment income, interest for the quarter ending 2026-03-30 was $24.00K, a 500.00% increase year-over-year.
- Valion Bio, Inc. investment income, interest for the quarter ending 2025-12-31 was $12.00K, a 100.00% increase year-over-year.
- Valion Bio, Inc. investment income, interest for fiscal 2025 was $23.00K, a 283.33% increase from fiscal 2024.
- Valion Bio, Inc. investment income, interest for fiscal 2024 was $6.00K.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.00K 10-Q · filed 2026-08-14 | $35.00K 10-Q · filed 2026-08-14 | ||
| 2026-03-31 | $24.00K 10-Q · filed 2026-05-14 | |||
| 2026-03-30 | $24.00K 10-Q · filed 2026-05-14 | $36.00K derived: sum of 2 quarters · filed 2026-05-14 | $40.00K derived: sum of 3 quarters · filed 2026-05-14 | $43.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $16.00K derived: sum of 2 quarters · filed 2026-03-30 | $19.00K derived: sum of 3 quarters · filed 2026-08-14 | $23.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $4.00K 10-Q · filed 2025-11-14 | $7.00K derived: sum of 2 quarters · filed 2026-08-14 | $11.00K 10-Q · filed 2025-11-14 | $17.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $3.00K 10-Q · filed 2026-08-14 | $7.00K 10-Q · filed 2026-08-14 | $13.00K derived: sum of 3 quarters · filed 2026-08-14 | $13.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $4.00K 10-Q · filed 2026-05-14 | $10.00K derived: sum of 2 quarters · filed 2026-05-14 | $10.00K derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $6.00K derived: sum of 2 quarters · filed 2026-03-30 | $6.00K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |